The present invention relates generally to compositions for wound closure.
More specifically, the present invention provides human skin equivalents
engineered to express exogenous polypeptides (e.g., antimicrobial
polypeptides and keratinocyte growth factor 2) and compositions and
methods for making human skin equivalents engineered to express exogenous
polypeptides. In addition, the present invention provides methods for
treatment of wounds with human skin equivalents engineered to express
exogenous polypeptides.